Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | MTTP | P55157 | 10/20 | 0.47 |
| ▸ | APOB | P04114 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791009 | 0.85 | TRPV1 (0.55) | SMOTRPV1MTTPAPOBALDH1A1 | |
| SCHEMBL6801341 | 0.83 | SMO (0.61) | SMOTRPV1MTTPAPOBALDH1A1 | |
| SCHEMBL6801623 | 0.83 | NTRK1 (0.62) | TRPV1ALDH1A1 | |
| SCHEMBL6788109 | 0.82 | MTTP (0.56) | MTTPAPOBALDH1A1PTGS1SMN1; SMN2 | |
| SCHEMBL6801936 | 0.81 | SMO (0.48) | SMOTRPV1MTTPAPOBALDH1A1 | |
| SCHEMBL6793291 | 0.80 | PTGS1 (0.56) | MTTPAPOBPTGS1SMN1; SMN2 | |
| SCHEMBL6789828 | 0.80 | PTGS1 (0.58) | TRPV1MTTPAPOBALDH1A1PTGS1 | |
| SCHEMBL6793814 | 0.80 | SMO (0.59) | SMOTRPV1MTTPAPOBALDH1A1 | |
| SCHEMBL6793895 | 0.79 | FFAR1 (0.57) | MTTPAPOBALDH1A1PTGS1SMN1; SMN2 | |
| SCHEMBL6790246 | 0.79 | SMO (0.49) | SMOTRPV1MTTPAPOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | SMO 2094/4885TRPV1 3714/4885MTTP 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.